STOCK TITAN
  1. Home
  2. News
  3. TRIB

Trinity Biotech Plc - TRIB STOCK NEWS

Welcome to our dedicated news page for Trinity Biotech Plc (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Trinity Biotech Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Trinity Biotech Plc's position in the market.

News
Trinity Biotech plc to Host Investor Call
Rhea-AI Summary
Trinity Biotech plc (Nasdaq: TRIB) will host an investor call on January 31, 2024, to provide an update on business operations. The call will focus on the company's diagnostic solutions for the point-of-care and clinical laboratory markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.21%
Tags
conferences
-
News
Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya
Rhea-AI Summary
Trinity Biotech plc (Nasdaq: TRIB) has begun commercial shipments of its new rapid HIV screening test, TrinScreen HIV, to Kenya as part of the country's large HIV screening program. The initial purchase order is for 2.5 million tests, with commitments from sponsors to fund the procurement of all 10 million tests required for 2024. The global HIV screening market is estimated at 150 million tests annually, with the majority in sub-Saharan Africa.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Trinity Biotech Announces Management Changes
Rhea-AI Summary
Trinity Biotech plc (Nasdaq: TRIB) announced the promotion of John Gillard to President and Chief Executive Officer, and Des Fitzgerald as Interim Chief Financial Officer. Gillard, an experienced international business executive, aims to leverage his background to drive the company's growth and increase shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
management
News
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
Rhea-AI Summary
Trinity Biotech plc (Nasdaq: TRIB) received a notice from Nasdaq regarding non-compliance with the minimum market value of publicly held shares requirement. The company has until May 20, 2024, to regain compliance or face potential delisting from the Nasdaq Global Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.98%
Tags
none
-
News
Trinity Biotech Welcomes The Decision Of The High Court Of Kenya To Strike Out The Applications To Prevent the Procurement of TrinScreen HIV By The Kenyan Ministry of Health
Rhea-AI Summary
Trinity Biotech welcomes court decision in Kenya, allowing the sale of TrinScreen HIV test kits to the Ministry of Health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.55%
Tags
none
-
News
Trinity Biotech Announces Q2 2023 Financial Results
Rhea-AI Summary
Trinity Biotech plc announces Q2 2023 results with $13.9m in revenue, a 3% decrease from Q1. Diabetes consumables revenue increased 10% over Q1, with a 70% increase in Asia. Clinical Chemistry and Syphilis product lines show positive momentum. Revenue outlook for Q3 is $14m to $15m. Haemoglobins franchise expects strong performance in H2 2023. Diabetes consumables expected to increase over 20% in H2. Strategic instrument placements and supply chain improvements aim to expand market. FDA clearance for Premier Resolution System. Partnership to maximize Sjogrens opportunity. TrinScreen HIV test launch in Kenya. Operational transformation initiatives for cashflow improvement. Headcount reduction of 20% by end of Q4 2023. Manufacturing optimization for Diabetes A1c consumables and instrument. Savings of over $1.5m expected. Supply chain optimization aims for 40%-50% savings in materials costs. Improved reagent column system in development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
earnings
News
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results
Rhea-AI Summary
Trinity Biotech plc to report financial results for Q2 FY2023 on October 3, 2023. Conference call scheduled at 11:00am ET. Webcast available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
earnings
-
News
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Trinity Biotech received notice from Nasdaq for non-compliance with minimum bid price rule. Stock will continue trading but must meet $1.00 bid price for 10 consecutive days within 180-day period to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
none
-
News
Trinity Biotech Announces That It Has Received 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System
Rhea-AI Summary
Trinity Biotech has received FDA clearance for the Premier Resolution System, an automated analyzer for hemoglobin quantification and detection of variants. The system is now cleared for sale in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
none
News
Trinity Biotech Announces Q1 2023 Financial Results
Rhea-AI Summary
Trinity Biotech plc announced its Q1 2023 results, reporting a total revenue of $17.2 million. Excluding certain products and a disposed division, revenue for the quarter was $14 million, a 2.0% increase from Q1 2022. The company experienced growth in Autoimmune, Clinical Chemistry, and diabetes HbA1c consumable products. However, there were lower revenues from low-margin diabetes instrument deliveries. The development of the Premier 9210 diabetes HbA1c instrument is on track for a 2024 rollout, with improved features and expanded operating margins. Trinity Biotech is focused on expanding its market access in China and Brazil. The company also expects significant orders for its TrinScreen HIV test in Kenya. Trinity Biotech completed the sale of its Fitzgerald Industries division, generating $30 million in proceeds and reducing debt. The company will participate in the AACC annual scientific meeting and clinical lab expo in July.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.89%
Tags
earnings
Stock TRIB logo
Trinity Biotech Plc

Nasdaq:TRIB

TRIB Rankings

#5275 Ranked by Market Cap
#4935 Ranked by Stock Gains
N/A Ranked by Dividends

TRIB Stock Data

14.21M
69.32M
29.31%
39.27%
0.02%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Ireland
Bray

About TRIB

since its formation in 1992, trinity biotech has actively pursued the aim of becoming a leading player in the international diagnostics industry. through a combination of sustained, organic growth and an acquisition-led strategy, the company has assembled an impressive product portfolio and achieved the highest standards of excellence in developing, manufacturing and marketing diagnostic products. the test kits manufactured by trinity biotech are used in the clinical laboratory and point-of-care segments of the diagnostic market to detect infectious diseases, sexually transmitted diseases, autoimmune and haemoglobin disorders, and detect, monitor and control diabetes. the company is also a significant provider of raw materials to the life sciences industry. trinity biotech, which has its headquarters in ireland, employs in excess of 350 people and markets its portfolio of over 400 products to customers in 80 countries around the world. it reaches this worldwide market by combining the